ClinicalTrials.gg
TerminatedNCT03395132Updated Feb 24, 2025

Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema

A Phase 3 interventional study of Fucicort® Lipid cream and Fucidin® cream in Infected Atopic Dermatitis/Eczema, sponsored by LEO Pharma. Terminated at 15 sites in China. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to business strategic reasons, LEO Pharma has decided to close down the FCF-38 trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
10th of 12
68 · median 178
Started
2018
with 1 other
Phase 3
7 of 13
none open now
Registered
4th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 4th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

The trial is designed to compare the efficacy and safety of Fucicort® Lipid cream with the combination treatment of Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream, or Fucicort® Lipid cream vehicle, when applied twice daily for two weeks. The trial is designed to demonstrate that treatment with Fucicort® Lipid cream is not inferior to the combination treatment with the mono component drugs, Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream and that treatment with Fucicort® Lipid cream is superior to the treatment with Fucicort® Lipid cream vehicle. This is a 3-arm, parallel group, active- and vehicle-controlled trial comparing the efficacy and safety after 14 days treatment of Fucicort® Lipid cream, to Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream, or Fucicort® Lipid cream vehicle, in subjects with clinically infected AD/eczema.

03

Conditions studied

  • Infected Atopic Dermatitis/Eczema

Browse trials for

04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AD/eczema as defined by Williams's criteria with clinical signs of infected AD/eczema on trunk and/or extremities such as fluid drainage, blistered skin, white or yellow pus, severe itchiness and new burning sensation
  • A minimum score of 1 for each of the signs in the m-EASI score in at least one of the pre-defined body areas (trunk and/or extremities)
  • Subjects between 2 and 65 years of age

Exclusion criteria

Exclusion Criteria:

  • History of concurrent diseases that could interfere with trial assessments or pose a safety concern
  • Subjects with other skin lesions, e.g. scarring, tattoos, or hyperpigmentation on the treatment area that could interfere with assessments
  • Clinical findings such as severe heart, liver, kidney and lung deficiency, which will be impacted by the trial procedures at the investigator's discretion
  • Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the last 4 weeks prior to randomisation at investigator's discretion
  • Use of prohibited medication, i.e.

    1. Systemic treatment with or immunomodulating drugs(including Leigongteng) or within 28 days prior to randomisation
    2. Use of topical or systemic antibiotics and anti-histamines within 14 days prior to randomisation
    3. Phototherapy (e.g. PUVA, UVA or UVB therapy) within 28 days prior to randomisation
    4. Topical treatment with immunomodulators (e.g. pimecrolimus, tacrolimus) within 14 days prior to randomisation
    5. Topical treatment with corticosteroids or any other topical treatment within 7 days prior to randomisation
    6. Use of any non-prescribed systemic or cutaneous medication within 7 days prior to randomisation
    7. The use of analgesics at the discretion of the investigator is allowed before and during the trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Fucicort® Lipid cream

    Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.

    Drug: Fucicort® Lipid cream

  • Active comparator
    Fucidin cream +betamethasone cream

    The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.

    Drug: Fucidin® cream · Drug: betamethasone (Lianbang Beisong®) cream

  • Placebo comparator
    Vehicle cream

    The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.

    Drug: Fucicort® Lipid cream vehicle

Interventions

  • DrugFucicort® Lipid cream

    The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.

  • The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.

  • DrugFucicort® Lipid cream vehicle

    The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.

  • The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.

06

What researchers measure

Primary outcomes

  1. The percentage change in modified Eczema Area and Severity Index (m-EASI) on trunk and extremities at Day 15

    The percentage change in modified Eczema Area and Severity Index (m-EASI) on trunk and extremities from baseline to Day 15. The m-EASI is a composite score evaluating the severity of 4 clinical signs (erythema, oedema/induration/papulation, excoriation, and lichenification) and the extent of the disease on each of 3 body regions (upper limbs, trunk, and lower limbs) by use of standard scales. The maximum total score is 64.8, with higher values indicating more severe and/or more extensive condition.

    Time frame: from baseline to Day 15

Secondary outcomes

  1. Investigator's Global Assessment (IGA) at Day 15

    The IGA of disease severity on the body (trunk and extremities, excluding the hands, head, and neck) will be assessed based on a visual evaluation by use of definitions of severity ranging from 0 (clear) to 5 (very severe).

    Time frame: at Day 15

  2. Controlled disease according to IGA

    Controlled disease according to IGA at Day 15, defined as subjects having at least 'moderate' disease at baseline achieving 'clear' or 'almost clear' disease severity or subjects having 'mild' disease at baseline achieving 'clear' according to IGA.

    Time frame: at Day 15

  3. Proportion of patients with successful bacteriological response

    Proportion of patients with successful bacteriological response, defined as pathogens present on target lesion at baseline and either: a) no pathogen present on target lesion at Day 15 ('confirmed eradication') or b) no swab taken at Day 15 as no lesion was evident ('presumptive eradication').

    Time frame: at Day 15

  4. Adverse event (AE)/serious adverse event (SAE) frequency

    Adverse event (AE)/serious adverse event (SAE) frequency by preferred term. Ongoing (serious or non-serious) AE with a possible, probable, or non-assessable relationship to the IMP at the last visit in the treatment phase. The investigator should follow up on the outcome for 14±2 days or until the final outcome is determined. This follow-up visit can be made either as a phone call or as a regular visit according to the investigator's discretion.

    Time frame: baseline to Day 15 and 14±2 days follow up or until the final outcome is determined

07

Study locations

15 sites
  • Beijing Children's Hospital, Capital Medical University
    Beijing, Beijing Municipality 100045, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
  • Guangdong General Hospital
    Guangzhou, Guangzhou 510080, China
  • Tongji Hospital of Tongji Medical College of Huazhong Univ. of Science & Technology
    Wuhan, Hubei 430030, China
  • Dermatology Hospital, China Academy of Medicine and Science
    Nanjing, Jiangsu 210042, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116023, China
  • The Chinese People's Liberation Army General Hospital Of Northern Theater
    Shenyang, Liaoning 110000, China
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning 110016, China
  • Tangdu Hospital
    Xi'an, Shan'xi 710038, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
  • Shanghai Huashan Hospital
    Shanghai, Shanghai Municipality 200040, China
  • Children's Hospital of Shanghai
    Shanghai, Shanghai Municipality 200062, China
  • Children's Hospital, Capital Institute of Pediatrics
    Beijing, 100020, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in May 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2018
First posted
Jan 10, 2018
StartActual
Jul 31, 2018
Primary completionActual
May 9, 2019
CompletionActual
May 9, 2019
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03395132
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Jan 10, 2018
Start date
Jul 31, 2018
Primary completion
May 9, 2019
Completion
May 9, 2019
Last update
Feb 24, 2025

Study contacts

Study Director
study director · LEO Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion